Skip to main navigation Skip to search Skip to main content

Successful treatment of relapsed lymphomatoid granulomatosis with bexarotene

  • Sigrid E. Berg
  • , Lisa H. Downs
  • , Drew A. Torigian
  • , Elise A. Chong
  • , Donald E. Tsai
  • , Mariusz A. Wasik
  • , Stephen J. Schuster
  • University of Pennsylvania

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Lymphomatoid granulomatosis is a rare lymphoproliferative disorder involving the lungs, skin and other organs. Advanced-stage disease does not tend to respond well to cytotoxic chemotherapy and is associated with a poor prognosis. We present a case of successful treatment of relapsed lymphomatoid granulomatosis with bexarotene, a novel retinoid agent.

Original languageEnglish
Pages (from-to)1544-1546
Number of pages3
JournalCancer Biology and Therapy
Volume7
Issue number10
DOIs
StatePublished - Oct 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Bexarotene
  • Lymphomatoid granulomatosis
  • Lymphoproliferative disease
  • New drugs for lymphoma
  • Novel therapeutics
  • Retinoid
  • T-cell lymphoma

Fingerprint

Dive into the research topics of 'Successful treatment of relapsed lymphomatoid granulomatosis with bexarotene'. Together they form a unique fingerprint.

Cite this